Sep 2026
Fabrication and Optimization of Gelucire® 44/14-Stabilized Erlotinib Nanoliposomes for Enhanced Anticancer Efficacy in Lung Cancer
The developed nanoliposomal system offers significant clinical advantages including potential for enhanced tumor targeting, reduced dosing frequency, and minimized systemic toxicity, pending in vivo validation, and improved therapeutic outcomes.
Mayur R. Nikam, D. Sonawane, A. Pawar
· BioNanoScience · 0 citations